Phathom Pharmaceuticals (PHAT) Prepaid Assets (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Prepaid Assets of $8.3 million for Q2 2026, down 43.21% year-over-year from $14.6 million in Q2 2025, and down 1.58% quarter-over-quarter from $8.4 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Prepaid Assets (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Prepaid Assets for 9 consecutive years, with $8.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Prepaid Assets fell 43.21% year-over-year to $8.3 million; the TTM figure through Jun 2026 stood at $8.3 million (down 43.21% YoY), while the FY2025 annual figure was $15.4 million, down 26.42% from the prior year.
- Prepaid Assets retreated to $8.3 million in Q2 2026 per PHAT's latest filing, from $8.4 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $20.9 million in Q4 2024 and bottomed at $975000.0 in Q3 2022.
- Historically, Prepaid Assets has averaged $11.0 million across 5 years, with a median of $12.8 million in 2023.
- Annual changes were most pronounced in 2023 — Prepaid Assets surged 1226.97% — and 2026, when it plunged 43.21%.
- Phathom Pharmaceuticals' Prepaid Assets stood at $5.1 million in 2022, then soared by 157.34% to $13.2 million in 2023, then soared by 58.15% to $20.9 million in 2024, then retreated by 26.42% to $15.4 million in 2025, then slumped by 45.93% to $8.3 million in 2026.
- Business Quant data shows PHAT's Prepaid Assets at $8.3 million in Q2 2026, $8.4 million in Q1 2026, and $15.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.30 Mn |
| Mar 31, 2026 | 8.44 Mn |
| Dec 31, 2025 | 15.35 Mn |
| Sep 30, 2025 | 13.23 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Mar 31, 2025 | 13.06 Mn |
| Dec 31, 2024 | 20.87 Mn |
| Sep 30, 2024 | 14.98 Mn |
| Jun 30, 2024 | 15.50 Mn |
| Mar 31, 2024 | 12.75 Mn |
| Dec 31, 2023 | 13.19 Mn |
| Sep 30, 2023 | 12.94 Mn |
| Jun 30, 2023 | 8.76 Mn |
| Mar 31, 2023 | 10.27 Mn |
| Dec 31, 2022 | 5.13 Mn |
| Sep 30, 2022 | 975,000.00 |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 7.65 Mn |
| Dec 31, 2021 | 3.27 Mn |
| Sep 30, 2021 | 695,000.00 |